Patients receiving IL-23 inhibitors exhibited a significantly greater resolution of enthesitis compared to placebo (RR = 1.46; 95% CI: 1.29–1.64; p < 0.001), with no evidence of heterogeneity (I2 = 0.0%; Figure 4B). Here, IL23A is linked to enthesitis.